PacBio HiFi sequencing. The partnership combines DNA methylation episignature analysis with genomic and multi-omics ...

Key TakeawaysPacBio shares fell 8% after AI drug-discovery company TychoBio said it will use PacBio’s long-read sequencing on more than 10,000 samples. The deal backs PacBio’s pitch to AI companies, ...

TychoBio will test candidate RNA therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. Those results will become training data for models ...

TychoBio will test candidate RNA therapies across multiple cell types and use PacBio sequencing to measure changes in the transcriptome following treatment. The resulting data will be used to train ...

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after ...

PacBio PACB recently announced the worldwide commercial availability of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi sequencing platform. The launch is expected to ...

Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like Illumina. Read why PACB stock is a buy.

PacBio has announced its participation in the 1000 Genomes Long Read Sequencing Project, contributing long-read transcriptome data to enhance this significant human genomics initiative. Through ...

Pacific Biosciences of California (PACB) surged intraday on Friday after its 2Q 2013 earnings release. By midday, the company's stock had jumped over 8%. Pacific Biosciences is a developing ...